Skip to main content

Advertisement

Table 1 Studies of indacaterol included in the study-level pooled analysis (all studies) and patient-level analysis (B2335S and B2356)

From: Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

Design Patients Indacaterol dose, μg Pbo For Sal Tio
   18.75 37.5 75 150 300 600     
Cross-over, 14-day 96      144   72   72  
Parallel-group, 52-week 1732      437 428 432 435   
Parallel-group 26-week 2059    130 420 418 123 425 123   420
Crossover, 14-day 68      66   66   65  
Parallel-group, 12-week 416     211    205    
Parallel-group, 12-week 347*     114 116   117    
Parallel-group, 26-week 563     188 188   187    
Parallel-group, 26-week 1002     333    335   334  
Parallel-group, 12-week 323    163     160    
Parallel-group, 12-week 318    159     159    
Parallel-group, 12-week 552 92 91 94 92    91   92  
  7476 92 91 546 1358 1369 551 2249 558 563 420
  1. All studies were placebo-controlled. Values are numbers of patients (the sum of totals across the columns for indacaterol dose and comparators is greater than the total number of patients randomized due to the inclusion of cross-over studies). *Asian patients; 73 morning dosing vs 71 evening dosing. Pbo = placebo; For = formoterol 12 μg bid; Sal = salmeterol 50 μg bid; Tio = tiotropium 18 μg qd